Reference
Worked example: Alder Ridge Health
Part of the KPI Architecture skill · loaded on demand from SKILL.md
Read this when you want to see a complete, end-to-end output: strategy map, scorecard, measure-definition sheets, value-realisation ledger with stage gates, the P&L reconciliation, and the review cadence, with numbers that tie.
Contents
- Client situation and inputs received
- Financial anchor and value gap
- Strategy map
- Linkage hypotheses (the arrows, written out)
- Scorecard: measures, lead/lag, owners, baselines, targets
- Measure-definition sheets (three shown in full)
- Value-realisation ledger at month 9
- Reconciliation: ledger to P&L
- Review cadence and what happened at the month-9 review
- What the partner challenged before it went to the client
1. Client situation and inputs received
Alder Ridge Health is a non-profit regional health system serving a mid-sized metropolitan area and the surrounding counties in the US Southeast. Five acute hospitals (one 520-bed tertiary hub and four community hospitals of 180 to 320 beds, 1,640 licensed beds in total), 38 outpatient clinics, an employed medical group of about 640 physicians and advanced practice providers, and roughly 14,500 employees. Total operating revenue $2,400M; 82,000 inpatient admissions, 128,000 adjusted admissions and 700,000 adjusted patient days a year. Operating EBITDA (operating income before depreciation, amortisation and interest) is $144.0M, a 6.0 percent margin; after $112M of depreciation and interest the operating margin is 1.3 percent, and it has been below 2 percent for two years. The bond rating agency moved the outlook to negative last year. The board's finance committee has set a target of 8.5 percent operating EBITDA margin by the end of FY3, the level it judges necessary to fund the capital plan and hold the rating.
The executive team named in this example:
| Role | Name | Short form used in tables |
|---|---|---|
| Chief executive | Margaret Okafor | CEO |
| Chief financial officer | Daniel Reiss | CFO |
| Chief operating officer | Priya Venkataraman | COO |
| Chief medical officer | Dr Thomas Lindqvist | CMO |
| Chief nursing officer | Angela Torres | CNO |
| President, employed medical group | Dr Samuel Boateng | President, Medical Group |
| Chief human resources officer | Laura Bennett | CHRO |
| Chief information officer | Rachel Huang | CIO |
| Chief quality officer | Dr Nadia Rahman | CQO |
| Vice president, revenue cycle | Karen Whitfield | VP Revenue Cycle |
| Vice president, supply chain and purchased services | Marcus Delgado | VP Supply Chain |
| Chief transformation officer | Elena Sorensen | CTO |
Inputs received from upstream skills:
- From
strategic-choice: the chosen position is "the reliable system of care close to home": the same outcomes as the academic centre in the city, delivered in the region, with a bed or an appointment available when it is needed. It is delivered through clinical standardisation on the twelve highest-volume conditions, patient flow, a stable employed nursing workforce, ambulatory access, and revenue integrity. - From
execution-planning: six chartered initiatives with sponsors and owners, a transformation office (TO) of five people led by the chief transformation officer reporting to the CEO, and a 90-day plan already under way. - From
value-driver-modeling: the baseline P&L and the driver tree that sizes each initiative.
What was missing and assumed: no history of initiative tracking exists, so all baselines are set at FY0 actuals; the finance function has agreed to provide a controller two days a week to the TO. The four-line financial anchor uses the hospital equivalents of the standard lines: total operating revenue, labour cost (salaries, wages, benefits and contract labour), non-labour operating expense (supplies, drugs, purchased services and other), and operating EBITDA. The reconstruction from the management accounts is labelled as such and signed by the CFO.
2. Financial anchor and value gap
| Line | FY0 actual | FY3 target | Change |
|---|---|---|---|
| Total operating revenue | $2,400.0M | $2,640.0M | +$240.0M (3.2 percent CAGR) |
| Labour cost (salaries, wages, benefits, contract labour) | $1,344.0M (56.0 percent of revenue) | $1,425.6M (54.0 percent) | +$81.6M |
| Non-labour operating expense (supplies, drugs, purchased services, other) | $912.0M (38.0 percent) | $990.0M (37.5 percent) | +$78.0M |
| Operating EBITDA | $144.0M (6.0 percent) | $224.4M (8.5 percent) | +$80.4M |
Operating EBITDA bridge FY0 to FY3, run-rate basis:
| Component | $M |
|---|---|
| FY0 operating EBITDA | 144.0 |
| Initiative run-rate value (six boulders plus sand, see ledger) | +106.4 |
| Organic growth contribution ($160M of the $240M incremental revenue is payer rate and demographic growth independent of the programme, at 20 percent contribution after variable cost) | +32.0 |
| Wage and non-labour inflation on the base, three years, net of contracted payer rate increases | -58.0 |
| FY3 operating EBITDA | 224.4 |
So the initiative portfolio must deliver $106.4M of run-rate value for the plan to land at $224.4M, and the value gap the board cares about is $80.4M. The remaining $80M of incremental revenue is initiative-driven (retained admissions from freed capacity, ambulatory growth) and sits inside the run-rate figure. Coverage of identified initiatives over the required value is examined in section 7.
Year-1 plan: revenue $2,470M, initiative value landing in the FY1 P&L $38.0M, one-off implementation costs $9.5M, headwinds net of organic contribution $6.5M. FY1 operating EBITDA plan: 144.0 + 38.0 - 9.5 - 6.5 = $166.0M, a 6.7 percent margin.
3. Strategy map
Read bottom to top. Objectives are outcomes, not activities. Arrows are listed in section 4.
Financial
- F1 Reach 8.5 percent operating EBITDA margin ($224.4M) by FY3
- F2 Reduce cost per unit of care: labour cost per adjusted patient day to $1,840 and supply and drug cost per adjusted admission to $3,510 (productivity: workforce, flow, standardisation)
- F3 Grow net revenue to $2,640M (growth: access, retained capacity, quality-linked payments)
- F4 Collect what is earned: final denial write-offs from 1.9 to 1.0 percent of net revenue (productivity: revenue integrity)
Customer: patients, families, referring clinicians and payers (value proposition: the reliable system of care close to home)
- C1 Patients get a bed or an appointment when they need one, and referrals stay in the system
- C2 Patients recover without avoidable harm or unplanned return
- C3 Patients and families would recommend the hospital
Internal process
- I1 Every eligible patient is treated on the agreed care pathway (clinical standardisation, twelve conditions)
- I2 Patients move through the hospital without waiting on the system (flow)
- I3 Every shift is staffed to plan with the system's own workforce
- I4 Ambulatory capacity is filled and new patients are seen within a week
- I5 Every encounter is documented, coded and billed correctly the first time
Learning and growth
- L1 The nursing workforce is stable and experienced (human capital)
- L2 Physicians lead pathway and service-line performance, with incentives aligned to system outcomes (organisation capital)
- L3 Clinical and operational data is timely and trusted: real-time bed status, central scheduling, claim edits in the EHR (information capital)
Strategic themes (the vertical slices through the map): Clinical reliability (L2, I1, C2, F2), Flow and capacity (L3, I2, C1, F3), Workforce stability (L1, I3, C3, F2), Access and revenue integrity (L3, I4, I5, C1, F3, F4).
4. Linkage hypotheses (the arrows, written out)
Each arrow is an if-then statement with the lead and lag measure pair and an expected lag time. These are the hypotheses the quarterly review tests.
| Arrow | Hypothesis | Lead measure (tail) | Lag measure (head) | Expected lag |
|---|---|---|---|---|
| L1 to I3 | If first-year RN turnover falls from 31 to 18 percent, contract-labour share of nursing hours falls from 11.0 to 4.0 percent | First-year RN turnover, percent | Contract-labour share of nursing hours, percent | 2 quarters |
| L2 to I1 | If all 12 pathways have a physician-nurse dyad in post and an order set live in the EHR, order-set adherence rises from 54 to 85 percent | Pathways with dyad in post and order set live, of 12 | Pathway order-set adherence, percent | 1 quarter |
| L3 to I2 | If the real-time bed board and discharge-readiness flag are live in all five hospitals, discharges before noon rise from 18 to 40 percent | Hospitals live on real-time bed board, of 5 | Discharges before noon, percent | 1 quarter |
| L3 to I4 | If central scheduling with standard templates covers all 38 clinics, third-next-available appointment in primary care falls from 21 to 7 days | Clinics on central scheduling, of 38 | Third-next-available appointment, days | 1 quarter |
| L3 to I5 | If claim-edit rules and the documentation-query worklist are live in the EHR, clean-claim rate rises from 84 to 95 percent | Claim edits and query worklist live, yes/no | Clean-claim rate, percent | 1 quarter |
| I1 to C2 | If adherence reaches 85 percent, risk-adjusted 30-day readmission falls from 15.2 to 13.0 percent | Pathway order-set adherence | 30-day readmission, risk-adjusted, percent | 2 quarters |
| I1 to F2 | If adherence reaches 85 percent, supply and drug cost per adjusted admission falls 6.4 percent through preference-item and formulary standardisation | Pathway order-set adherence | Supply and drug cost per adjusted admission, $ | 2 quarters |
| I2 to C1 | If observed-to-expected length of stay falls from 1.12 to 1.00, ED boarding hours fall from 92,000 to 40,000 a year | Observed-to-expected length of stay | ED boarding hours, admitted patients | 1 quarter |
| I3 to F2 | If contract-labour share falls to 4.0 percent, labour cost per adjusted patient day falls from $1,920 to $1,840 | Contract-labour share of nursing hours | Labour cost per adjusted patient day, $ | 1 quarter |
| I3 to C3 | If shifts staffed to plan rise from 82 to 95 percent, the HCAHPS "would recommend" top-box score rises from 68 to 74 percent | Shifts staffed to plan, percent | HCAHPS recommend, top-box percent | 2 quarters |
| I4 to C1 | If third-next-available falls to 7 days and slot utilisation rises from 78 to 90 percent, referral keepage rises from 61 to 70 percent | Third-next-available appointment, days | Referral keepage, percent | 2 quarters |
| I5 to F4 | If clean-claim rate reaches 95 percent, initial denials fall from 11.8 to 7.0 percent and final denial write-offs fall from 1.9 to 1.0 percent of net revenue | Clean-claim rate | Final denial write-offs, percent of net revenue | 2 quarters |
| C1 to F3 | If ED boarding hours fall to 40,000 and keepage reaches 70 percent, retained admissions and ambulatory visits take net revenue to $2,640M | ED boarding hours; referral keepage | Net revenue, $M | 3 to 4 quarters |
| C2 to F3 | If readmission falls to 13.0 percent and hospital-acquired conditions to 2.4 per 1,000 patient days, the quality-linked payments in commercial and government contracts (about $9M a year at risk) are earned rather than forfeited | 30-day readmission; hospital-acquired conditions | Quality-linked contract payments earned, $M (component of F3) | 4 quarters |
| C3 to F3 | If recommend reaches 74 percent, inpatient share in the primary service area holds at or above 38.5 percent while capacity grows | HCAHPS recommend | Inpatient market share, primary service area, percent (component of F3) | 4 quarters |
Linkage test applied: every objective has at least one inbound and one outbound arrow except the L-row (no inbound) and F1 (no outbound; F2, F3 and F4 feed F1 by arithmetic). No orphan objectives. Total arrows: 15. The first draft had 28; the executive team cut the ones nobody would defend under questioning, including "engagement drives everything" and three arrows from data quality to financial outcomes with no process in between.
5. Scorecard: measures, lead/lag, owners, baselines, targets
Twenty measures. Frequency is the review frequency, not the data-capture frequency.
| Ref | Objective | Measure | Type | Owner | Baseline FY0 | FY1 target | FY3 target | Freq |
|---|---|---|---|---|---|---|---|---|
| F1 | Margin | Operating EBITDA / total operating revenue, percent | Lag | CFO | 6.0 | 6.7 | 8.5 | Monthly |
| F2 | Cost per unit of care | Labour cost per adjusted patient day, $ | Lag | COO | 1,920 | 1,890 | 1,840 | Monthly |
| F2 | Cost per unit of care | Supply and drug cost per adjusted admission, $ | Lag | VP Supply Chain | 3,750 | 3,650 | 3,510 | Monthly |
| F3 | Revenue | Net revenue, $M | Lag | CEO | 2,400 | 2,470 | 2,640 | Monthly |
| F4 | Revenue integrity | Final denial write-offs, percent of net revenue | Lag | CFO | 1.9 | 1.5 | 1.0 | Monthly |
| C1 | Access and retention | ED boarding hours, admitted patients, annualised | Lag | COO | 92,000 | 65,000 | 40,000 | Monthly |
| C1 | Access and retention | Referral keepage, percent of in-system referrals scheduled in-system | Lag | President, Medical Group | 61 | 65 | 70 | Quarterly |
| C2 | Outcomes | 30-day all-cause readmission, risk-adjusted, percent | Lag | CMO | 15.2 | 14.2 | 13.0 | Monthly |
| C2 | Outcomes | Hospital-acquired conditions per 1,000 patient days | Health | CQO | 3.1 | 2.8 | 2.4 | Monthly |
| C3 | Experience | HCAHPS "would recommend", top-box percent | Lag | CNO | 68 | 71 | 74 | Quarterly |
| I1 | Pathways | Pathway order-set adherence, percent of eligible encounters | Lead | CMO | 54 | 78 | 85 | Weekly |
| I2 | Flow | Discharges before noon, percent | Lead | COO | 18 | 32 | 40 | Weekly |
| I2 | Flow | Observed-to-expected length of stay | Lag | COO | 1.12 | 1.05 | 1.00 | Weekly |
| I3 | Staffing | Contract-labour share of nursing hours, percent | Lead | CNO | 11.0 | 7.0 | 4.0 | Weekly |
| I3 | Staffing | Shifts staffed to plan, percent (pairing for contract-labour reduction) | Health | CNO | 82 | 90 | 95 | Weekly |
| I4 | Ambulatory access | Third-next-available appointment, primary care, days | Lead | President, Medical Group | 21 | 12 | 7 | Weekly |
| I5 | Revenue integrity | Clean-claim rate, percent | Lead | VP Revenue Cycle | 84 | 92 | 95 | Weekly |
| L1 | Workforce | First-year RN turnover, percent | Lead | CHRO | 31 | 22 | 18 | Monthly |
| L2 | Physician leadership | Pathways with dyad in post and order set live, of 12 | Lead | CMO | 3 | 12 | 12 | Monthly to 12, then retire |
| L3 | Data | Hospitals live on real-time bed board with discharge-readiness flag, of 5 | Lead | CIO | 1 | 5 | 5 | Monthly to 5, then retire |
Measures considered and rejected: "nurse education hours delivered" (activity, replaced by first-year turnover and the staffing measure it is supposed to drive); "number of order sets built" (kept only as an initiative milestone, not a scorecard measure); "patient portal enrolments" (not causal to anything on the map in this strategy period); "average daily census" (ambiguous: it rises when flow worsens as well as when demand grows, so it cannot be read without the flow measures beside it); "employee engagement score" (kept in the HR dashboard; first-year turnover is the measure on the arrow).
Two temporary measures carry retirement rules. "Pathways with dyad in post and order set live" is retired when it reaches 12 of 12 and replaced by "pathways with adherence below 75 percent for two consecutive months", which is the ongoing capability signal. "Hospitals live on real-time bed board" is retired at 5 of 5; the arrow's lag measure, discharges before noon, carries on.
6. Measure-definition sheets (three shown in full)
Measure: Pathway order-set adherence, percent (I1, lead)
| Field | Definition |
|---|---|
| Formula | Inpatient encounters with a principal diagnosis in one of the 12 pathway conditions (diagnosis-code list versioned by the CMO's office) where the pathway order set was used within the pathway's timing window and at least 80 percent of the required bundle elements were completed, divided by all encounters with a qualifying principal diagnosis discharged in the period. Excludes patients under 18, transfers in more than 24 hours after admission elsewhere, and patients placed on comfort care within 24 hours of admission. |
| Data source | EHR encounter table joined to the order-set usage log and the pathway element table by encounter ID. Principal diagnosis is taken from the final coded record, so the measure finalises about ten days after month end; the weekly figure uses provisional coding and is labelled as such. Diagnosis-code lists are versioned; use the version in force on the discharge date. |
| Frequency | Calculated daily on provisional coding; reviewed weekly at the TO meeting; reported monthly on final coding. |
| Owner | CMO (accountable). Data steward: clinical informatics analyst. |
| Baseline | 54.2 percent, FY0 full year, 31,400 qualifying encounters. |
| Target | 78 percent by end FY1; 85 percent by end FY2 and sustained. |
| Related measure (pairing) | 30-day readmission (C2) and supply and drug cost per adjusted admission (F2). Adherence rising while neither moves indicates order sets being opened and edited rather than followed; the share of order sets opened with more than 40 percent of elements removed is reported alongside the measure. |
| Value link | Feeds ledger initiative V2. Value is computed as (FY0 supply and drug cost per case for the condition minus actual cost per case) times cases in the period, at constant FY0 unit prices. |
| Double-count rule | V2 is measured on units per case at constant FY0 unit prices. Unit-price changes from contracting are attributed to the supply-chain sand initiatives, which are measured at constant volume and mix. The same rule is written in those initiatives' sheets. |
| Known limitations | The 12 conditions cover about 38 percent of discharges and 55 percent of supply and drug spend; conditions outside the list are not measured. Coding finalisation lags the month end. Reported with the exclusion count. |
| Change control | Any change to the formula, the bundle elements or the diagnosis-code lists requires CMO and CFO sign-off and a restated baseline. |
Measure: Contract-labour share of nursing hours, percent (I3, lead)
| Field | Definition |
|---|---|
| Formula | Hours worked by agency and travel registered nurses, licensed practical nurses and nursing assistants on inpatient and emergency units, divided by all worked nursing hours on those units, in the period. Internal float pool and per-diem employees count as the system's own staff. Overtime hours count as employed hours. |
| Data source | Timekeeping system, worked hours by job code and employer code, joined to the agency invoice file by cost centre and pay period. Both are versioned by pay period; use the pay period in which the hours were worked. |
| Frequency | Calculated per pay period (fortnightly); reviewed weekly at the TO meeting; reported monthly. |
| Owner | CNO. Data steward: nursing finance analyst. |
| Baseline | 11.0 percent, FY0 ($869,000 of 7.9M worked nursing hours). |
| Target | 7.0 percent end FY1; 4.0 percent end FY3. |
| Related measure (pairing) | Shifts staffed to plan (I3 health) and hospital-acquired conditions (C2 health). A falling contract share while shifts staffed to plan also falls means the share is being cut by running units short, which the CNO must approve unit by unit. |
| Value link | Feeds ledger initiative V1. Value is computed as (baseline share minus actual share) times worked nursing hours in the period times the contract premium ($52 per hour in FY0: average agency invoiced rate less average employed fully loaded rate, re-measured quarterly). |
| Double-count rule | V1 counts the premium on contract hours only. V3 (flow) counts hours removed from the roster by flex-unit closure at employed rates. A contract hour that V3 removes is counted in V3 at the employed rate and in V1 at the premium only; nothing is counted twice. Written in both sheets. |
| Known limitations | Agency hours in respiratory therapy, imaging and laboratory are outside the measure and tracked in sand. The premium varies by specialty (critical care highest); reported with the specialty mix. |
| Change control | Any change to the formula or the premium method requires CFO sign-off and a restated baseline. |
Measure: Realised initiative value, $M operating EBITDA (ledger, tier 3)
| Field | Definition |
|---|---|
| Formula | For each initiative at L4 or L5: the difference between actual P&L line(s) in the period and the agreed baseline for those lines, adjusted for the volume and payer-mix effects specified in the business case, summed across initiatives. Reported in-year (what has hit this fiscal year's P&L) and run-rate (annualised effect of changes already made). |
| Data source | Management accounts; initiative baseline sheets; adjustments computed by the TO controller and signed by the hospital division controller or the system controller. |
| Frequency | Monthly, at the value review. |
| Owner | CFO (accountable); TO controller (calculates). |
| Baseline | Defined per initiative at L2 and frozen. Baselines are not re-set unless the CFO approves a restatement, which is logged. |
| Rules | Value is reported as realised at L5 only. L4 value is shown as "assessed, not yet realised". Value observed in the P&L from initiatives still at L3 is shown as "early value, unvalidated". Forecast value for L1 and L2 is shown separately and never added to realised value in any headline number. One-off costs are shown on a separate line, never netted silently. |
7. Value-realisation ledger at month 9
Snapshot at the end of month 9 of FY1. All figures $M operating EBITDA. "Run-rate" is the annualised value once fully implemented; "FY1 in-year" is what the phasing plan expected to land in the FY1 P&L; "YTD in P&L" is finance-assessed value against the frozen baseline for initiatives at L3 and above. Only the L5 portion is reported as "realised" to the board; the stage split is shown below the table.
| ID | Initiative | Owner | Finance validator | Stage | Run-rate target | FY1 in-year target | YTD in P&L (M9) | FY1 forecast | Variance vs FY1 target | Next gate |
|---|---|---|---|---|---|---|---|---|---|---|
| V1 | Nursing workforce stabilisation (contract labour to 4 percent) | CNO | Hospital division controller | L4 | 22.0 | 9.0 | 6.8 | 9.6 | +0.6 | L5 review, month 11 |
| V2 | Clinical pathways and supply standardisation, 12 conditions | CMO | Hospital division controller | L3 | 15.5 | 4.5 | 2.1 | 3.6 | -0.9 | L4 planned month 14 |
| V3 | Patient flow and length of stay | COO | System controller | L3 | 18.0 | 6.0 | 3.4 | 5.2 | -0.8 | L4 planned month 13 |
| V4 | Ambulatory access and growth | President, Medical Group | Hospital division controller | L2 | 10.0 | 1.5 | 0.0 | 0.9 | -0.6 | L3 gate month 10 |
| V5 | Revenue integrity (denials, documentation) | VP Revenue Cycle | System controller | L3 | 13.5 | 4.0 | 2.3 | 3.8 | -0.2 | L4 planned month 15 |
| V6 | Purchased-services and non-clinical contract renegotiation | VP Supply Chain | System controller | L5 | 9.4 | 6.3 | 3.9 | 6.3 | 0.0 | Closed; sustain check month 12 |
| S | Sand: 26 initiatives each under $1.0M | Various | TO controller | L2 to L5 | 18.0 | 6.7 | 4.3 | 6.4 | -0.3 | Rolling |
| Total | 106.4 | 38.0 | 22.8 | 35.8 | -2.2 |
Stage split of the $22.8M year-to-date in P&L: L5 realised $6.5M (V6 3.9, sand 2.6); L4 assessed, awaiting finance sign-off $7.7M (V1 6.8, sand 0.9); L3 early value from initiatives still in execution $8.6M (V2 2.1, V3 3.4, V5 2.3, sand 0.8). The board report headline is "$6.5M realised", with the other two as separate bars.
Pipeline and coverage:
| Stage | Initiatives | Run-rate value $M |
|---|---|---|
| L5 Realised | 1 boulder, 7 sand | 14.0 |
| L4 Implemented, under finance assessment | 1 boulder, 5 sand | 25.4 |
| L3 In execution | 3 boulders, 8 sand | 53.1 |
| L2 Business case approved | 1 boulder, 6 sand | 13.9 |
| Subtotal L2 and above | 32 | 106.4 |
| L1 Validated, business case in preparation | 11 | 46.0 |
| L0 Ideas logged, unsized or rough | 44 | about 30 |
Stage subtotals tie to the run-rate column: V6 (9.4) plus 7 sand (4.6) = 14.0; V1 (22.0) plus 5 sand (3.4) = 25.4; V2, V3 and V5 (47.0) plus 8 sand (6.1) = 53.1; V4 (10.0) plus 6 sand (3.9) = 13.9. Sand total 4.6 + 3.4 + 6.1 + 3.9 = 18.0.
Coverage: L2-and-above value of $106.4M against required $106.4M run-rate is 100 percent, and against the $80.4M board gap is 132 percent. The public McKinsey rule of thumb is that value estimates attrite by around 70 percent from L1 to L5, so a pipeline of only 1.0x at L2 and 1.4x including L1 is thin. The TO's action from this review: move at least $25M of L1 value to L2 by month 12, and run a second idea-generation wave in the community hospitals and the clinics to refill L0.
Business-case logic for each boulder (so the run-rate numbers can be audited):
- V1: Contract-labour share of 7.9M worked nursing hours falls from 11.0 to 4.0 percent, 7.0 points, 553,000 hours at a $52 premium: $28.8M. Less $6.8M of retention investment (nurse residency programme, float-pool differentials, 20 float FTEs): $22.0M.
- V2: Supply and drug spend on the 12 pathway conditions is $264M (55 percent of $480M). A 7 percent reduction in units per case from preference-item and formulary standardisation is $18.5M, less $3.0M of dyad time, pharmacy and analytics staff: $15.5M.
- V3: Observed-to-expected length of stay from 1.12 to 1.00 on 380,000 inpatient days frees 380,000 x (1 - 1.00 / 1.12) = 40,700 bed-days. 55 percent are backfilled with retained admissions (22,400 bed-days at an average stay of 4.6 days is 4,870 admissions at $2,800 contribution): $13.6M. The other 45 percent close flex units (18,300 bed-days at $360 variable staffing cost): $6.6M. Total $20.2M, less $2.2M of care-management and discharge-lounge staff: $18.0M. Note: the backfill share was 65 percent in the charter and was tightened to 55 percent at L2 after the payer-mix review; the difference sits in the L2 log.
- V4: Slot utilisation from 78 to 90 percent on 1.05M template slots is 126,000 additional visits at $160 net revenue and 40 percent contribution: $8.1M. Keepage from 61 to 70 percent on 46,000 specialty referrals retains 4,140 referrals at $1,300 downstream contribution: $5.4M. Total $13.5M, less $3.5M of advanced practice providers and the central scheduling centre: $10.0M.
- V5: Final denial write-offs from 1.9 to 1.0 percent of $2,400M net revenue is $21.6M. A 75 percent realisation factor (some denials are payer behaviour, not documentation) gives $16.2M, less $2.7M of documentation specialists and denials analysts: $13.5M.
- V6: Renegotiated environmental services, linen, food service, IT maintenance and insurance contracts, $9.4M, landed in month 5 and validated in the management accounts for three consecutive months by month 8. FY1 in-year value is eight months, $6.3M.
8. Reconciliation: ledger to P&L
The month-9 value review reconciled the ledger to the management accounts:
| Line | Plan FY1 | Forecast FY1 (M9) | Comment |
|---|---|---|---|
| FY0 operating EBITDA | 144.0 | 144.0 | Frozen baseline |
| Initiative value in-year | +38.0 | +35.8 | Per ledger; V2, V3 and V4 behind, V1 ahead |
| One-off implementation costs | -9.5 | -10.1 | Nurse residency and float-pool start-up 3.6, EHR build (order sets, bed board, claim edits) 2.4, documentation and denials staffing ahead of value 1.5, scheduling centre fit-out 1.4, consulting support 1.2, including 0.6 of unplanned EHR contractor time on the bed board |
| Headwinds net of organic contribution (contract-labour rate inflation on remaining hours, specialty drug inflation, payer-mix shift toward government payers, less rate and volume growth) | -6.5 | -6.3 | Independent of the programme; tracked so the programme is neither blamed nor credited |
| FY1 operating EBITDA | 166.0 | 163.4 | 6.7 percent plan; 6.6 percent forecast on $2,462M revenue |
Check: 144.0 + 35.8 - 10.1 - 6.3 = 163.4. The management-accounts forecast produced by FP&A independently of the TO was $163.9M; the $0.5M difference was traced to the labour budget of one community hospital, which still holds the cost of a flex unit that V3 closes in month 11, and was logged.
9. Review cadence and what happened at the month-9 review
| Forum | Frequency | Attendees | Inputs | Decisions taken |
|---|---|---|---|---|
| TO initiative review | Weekly, Tuesday 07:30, 60 minutes | CTO, TO team, initiative owners in rotation | Milestone status, lead measures, blockers | Stage moves L1 to L4; unblocking; owner changes |
| Value review | Monthly, week 2 after close | CFO, system controller, CTO, TO controller, owners of initiatives at L4 or L5 | Ledger, management accounts, baseline adjustments | L5 sign-off; baseline restatements; forecast changes |
| Scorecard and strategy review | Quarterly | CEO, executive team, CTO | Scorecard, linkage-hypothesis status, ledger summary | Confirm or revise hypotheses; add or retire measures; reallocate resources |
| Board value report | Quarterly, to the finance committee and the quality committee jointly | Board | One-page: realised, assessed, forecast, pipeline, coverage; scorecard headlines | Investment approvals; target confirmation |
| Strategy map refresh | Annual, or on a strategic-choice change | CEO, executive team | Full map and scorecard | Rebuild map if the strategy changed; otherwise reconfirm |
At the month-9 scorecard review the hypothesis test produced two findings:
- Workforce stability is working as mapped. First-year RN turnover fell from 31 to 23 percent (year-end target 22); contract-labour share fell from 11.0 to 6.4 percent, already past the year-end target of 7.0; labour cost per adjusted patient day is down $24 at $1,896 against a one-quarter expectation of about $20 at this point. Shifts staffed to plan rose from 82 to 89 percent, so the reduction is real, not units running short. V1 is on course to exceed its FY1 in-year target.
- Clinical pathways are behind, and the map located the cause. Adherence rose from 54 to 66 percent (month-9 plan 72), and supply and drug cost per adjusted admission fell from $3,750 to $3,712 (plan $3,685). The lead measure upstream, pathways with dyad in post and order set live, reached 7 of 12 against a plan of 11: all twelve dyads are in post, but order sets are live for only seven conditions because the EHR build team was diverted to the bed board for V3. The lead did not move, so this is execution, not a failed hypothesis; readmission has in fact moved from 15.2 to 14.7 percent because the seven live pathways include the three highest-readmission conditions. The action was to move two EHR analysts from V4's central-scheduling build to the order-set build for ten weeks, accept a one-quarter delay to V4's L3 gate, and re-phase V2 in-year value from 4.5 to 3.6. The run-rate target of $15.5M was left unchanged.
10. What the partner challenged before it went to the client
- "Your headline said 'value delivered $22.8M'. It is $6.5M realised at L5, $7.7M under assessment at L4, and $8.6M early value from initiatives still at L3. Only the first is delivered. Rewrite the headline with the stage split." Done; the board page now shows realised, assessed, early and forecast as separate bars.
- "V1 and V3 both take labour hours out of the same units. Show me the double-count rule in the definition sheets." Added to both sheets (section 6): V1 counts the contract premium only, V3 counts hours removed at employed rates.
- "Readmission is your health measure for length of stay. If it is on a different page from observed-to-expected LOS, someone will cut stay and nobody will see the return visits until the quarter is over." The two measures now sit on the same row of the weekly flow page, and the V3 charter carries a response protocol: pause the flex-unit closures in any hospital where risk-adjusted readmission rises above 15.5 percent for two consecutive months.
- "The coverage line says 100 percent. Given the attrition data, that is a warning, not a comfort. Say so." Rewritten as in section 7.
- "Retire 'pathways with dyad and order set' when it hits 12, and the bed-board count when it hits 5. A scorecard measure that reads complete forever is dead weight." Retirement rules added.